NPPB and acute coronary syndrome: In the study by Liu et al. (2024), it was shown that in patients with acute coronary syndrome (ACS) and concomitant reduced LVEF, sacubitril/valsartan treatment and routine treatment led to improvement in the LVEF, NT-proBNP concentration, and left ventricular dimensions, while in the ARNI group, the assessed parameters were significantly improved over those in the routine group [15].